Extravan Approval Status
- FDA approved: No
- Brand name: Extravan
- Generic name: travoprost and timolol
- Company: Alcon
- Treatment for: Glaucoma
Extravan (Travoprost 0.004% + Timolol 0.5% Fixed Combination (TTFC)) is a prostaglandin analogue and beta-blocker combination intended for use in the treatment of glaucoma.
In September 2004, Alcon, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Extravan. While the combination is currently available in many countries, it remains commerically undeveloped in the United States.
Development Status and FDA Approval Process for Extravan
|Sep 17, 2004||Alcon Receives Approvable Letter for Extravan|
|Jan 28, 2004||Alcon Files NDA for Combination Drug to Treat Glaucoma; Releases PreliminaryClinical Data at Major Ophthalmology Meeting|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.